Fluidigm (FLDM) & Harvard Bioscience (HBIO) Financial Analysis

Fluidigm (NASDAQ: FLDM) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Profitability

This table compares Fluidigm and Harvard Bioscience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fluidigm -55.66% -98.85% -12.49%
Harvard Bioscience -3.70% 2.79% 1.75%

Analyst Recommendations

This is a breakdown of recent ratings for Fluidigm and Harvard Bioscience, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fluidigm 0 1 0 0 2.00
Harvard Bioscience 0 0 2 0 3.00

Fluidigm currently has a consensus price target of $6.10, indicating a potential upside of 27.62%. Harvard Bioscience has a consensus price target of $9.00, indicating a potential upside of 76.47%. Given Harvard Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe Harvard Bioscience is more favorable than Fluidigm.

Insider & Institutional Ownership

94.7% of Fluidigm shares are owned by institutional investors. Comparatively, 64.6% of Harvard Bioscience shares are owned by institutional investors. 2.2% of Fluidigm shares are owned by company insiders. Comparatively, 7.6% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Fluidigm has a beta of 2.99, meaning that its stock price is 199% more volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

Earnings & Valuation

This table compares Fluidigm and Harvard Bioscience’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fluidigm $101.94 million 1.82 -$60.53 million ($1.19) -4.02
Harvard Bioscience $101.88 million 1.80 -$860,000.00 $0.05 102.00

Harvard Bioscience has lower revenue, but higher earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Harvard Bioscience beats Fluidigm on 10 of the 14 factors compared between the two stocks.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

About Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion controllers, temperature controllers, microincubation systems, and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions. Harvard Bioscience, Inc. markets its products in approximately 100 countries through sales organization, Websites, catalogs, and distributors to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply